Alembic debuts generic Tarceva
Erlotinib tablets are indicated for treating metastatic non-small cell lung cancer patients with tumors with specific growth factor mutations.
Alembic is offering erlotinib tablets in dosage strengths of 25 mg, 100 mg and 150 mg.
The medication, which is the generic of OSI Pharmaceuticals’ Tarceva, is indicated for the treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
[Read more:Alembic rolls out generic Hygroton]
Alembic’s product will be available in 30-ct. bottles.